Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04309903
Other study ID # Necmettin Erb. Physiotherapy-2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 12, 2018
Est. completion date October 7, 2019

Study information

Verified date March 2020
Source Necmettin Erbakan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Uncertainty about how to treat existing hemophilic arthropathy (HA) is the most important issue that will increase functionality and joint health. Recent studies have shown that MT can be used safely for improving joint health, pain and ROM with no bleedings in PwH with elbow and ankle HA. Unlike MT studies in hemophilia, we investigated the effects of MT on important parameters such as muscle strength (MS), functional level, joint health, functional independence score in hemophilia (FISH) and kinesiophobia. These parameters are closely related to functional level and quality of life of PwH. Therefore, evaluation of these parameters and determining the effects of the MT on these parameters are very important for both PwH and also clinicians.


Description:

The aim of this study was to investigate the effects of manual therapy in addition to home exercise program on hemophilia functional independence level, joint health, kinesiophobia, functional level, range of motion, muscle strength and pain level in hemophilic individuals with lower extremity joint arthropathy. Hemophilic arthropathy was developed in at least one of the lower extremity joints and aged between 18-30 years 17 severe type hemophilic men were participated in the study. The participants were divided into two groups as Home Exercise Group (HEG) and Manual Therapy Group (MTG) by randomization method. While the HEG was performed the exercise program at home, in addition to the same HEG manual therapy were applied to the MTG by the same physiotherapist 3 days a week for 1 hour. Both groups were followed for a total of 5 weeks and pre-treatment evaluations were repeated post-treatment. The joint health of the hemophilics in both groups were evaluated with Hemophilia Joint Health Score (HJHS), their kinesiophobia level were evaluated with Tampa Kinesophobia Scale, their functionality with the Functional Independence Score in Hemophilia (FISH). In addition, Functional Reach, Timed Up and Go and 5 Times Sit-to- Stand tests were used for functional level. The range of motion was evaluated with a goniometer, muscle strength was measured with a digital dynamometer and pain level was assessed with a Visual Analogue Scale (VAS). Number of hemarthrosis decreased in both groups.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date October 7, 2019
Est. primary completion date April 15, 2019
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- Patients with hemophilia who have arthropathy developed in any of the lower extremity joints due to severe hemophilia and to be receiving regular prophylaxis (3*1500 IU/ per week), but not having regular physical activity and sports.

Exclusion Criteria:

- Patients with hemophilia who had any disease related to connective tissue, any surgery that affects lower limb function (joint debridement, fracture, prosthesis), any neurological disease or cognitive impairment that may affect functional level, any sensorial loss of peripheral nerve injury and did not attend their sessions and evaluations regularly.

Study Design


Intervention

Other:
Manual therapy
Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 * 10 repetitions, 20 sec of per reps and 10 sec of interval.

Locations

Country Name City State
Turkey Cukurova University Adana Saricam

Sponsors (1)

Lead Sponsor Collaborator
Necmettin Erbakan University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hemophilia Joint Health Score We used the index point of joints. Score ranged from 0 to 20. Low score indicates the good joint health 5 week
Primary Functional Independence Score in Hemophilia We used the functional independence of patients. Score ranged from 0 to 32. High score indicates the functional independence. 5 week
Primary Tampa Kinesiophobia Scale Score higher than 37 were associated with a high degree of kinesiophobia. 5 week
Secondary Range of motion Joint range was measured with a universal goniometer. 5 week
Secondary Muscle Strength It was measured with hand-held dynamometer. 5 week
Secondary Numerical Pain Scale It was used for assessment of activity and resting pain. 5 week
Secondary Frequency bleeding It was evaluated from the diaries kept by the patients 5 week
Secondary Functional Reach It was used to assess dynamic balance. 5 week
Secondary Timed Up and Go It was used to evaluate functional mobility, dynamic balance, fall risk and postural stability. 5 week
Secondary 5 Times Sit to Stand It was evaluated the functional strength of lower extremity, transitive movements, balance and fall risk. 5 week
See also
  Status Clinical Trial Phase
Recruiting NCT05617209 - In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
Completed NCT05039008 - Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy N/A
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Unknown status NCT02165592 - Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia N/A
Completed NCT02165462 - Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy N/A
Unknown status NCT02433782 - Myofascial Therapy in Patients With Hemophilic Arthropathy N/A
Completed NCT02546622 - ATHN 2: Factor Switching Study
Terminated NCT02586012 - Weight-based Dosing in Hemophilia A Phase 2
Completed NCT01232634 - Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles Phase 2
Completed NCT05104164 - Self-myofascial Release in Hemophilic Ankle Arthropathy N/A
Terminated NCT01191372 - First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients Phase 1
Completed NCT05173129 - Posture Analysis for Patients With Haemophilia N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Withdrawn NCT03996486 - Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia Phase 1
Completed NCT03842605 - Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia N/A
Completed NCT01708564 - A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B Phase 1
Completed NCT05549843 - Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle N/A
Recruiting NCT06010953 - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment Phase 1/Phase 2
Completed NCT05027230 - A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor Phase 1/Phase 2
Not yet recruiting NCT06014320 - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease